PL362986A1 - Zmodyfikowany czynnik stymulujący tworzenie kolonii granulocytów i makrofagów (GM-CSF) o obniżonej immunogeniczności - Google Patents

Zmodyfikowany czynnik stymulujący tworzenie kolonii granulocytów i makrofagów (GM-CSF) o obniżonej immunogeniczności

Info

Publication number
PL362986A1
PL362986A1 PL02362986A PL36298602A PL362986A1 PL 362986 A1 PL362986 A1 PL 362986A1 PL 02362986 A PL02362986 A PL 02362986A PL 36298602 A PL36298602 A PL 36298602A PL 362986 A1 PL362986 A1 PL 362986A1
Authority
PL
Poland
Prior art keywords
csf
stimulating factor
colony stimulating
macrophage colony
granulocyte macrophage
Prior art date
Application number
PL02362986A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL362986A1 publication Critical patent/PL362986A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL02362986A 2001-03-08 2002-02-28 Zmodyfikowany czynnik stymulujący tworzenie kolonii granulocytów i makrofagów (GM-CSF) o obniżonej immunogeniczności PL362986A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01105775 2001-03-08
PCT/EP2002/002148 WO2002070548A2 (en) 2001-03-08 2002-02-28 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity

Publications (1)

Publication Number Publication Date
PL362986A1 true PL362986A1 (pl) 2004-11-15

Family

ID=8176721

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02362986A PL362986A1 (pl) 2001-03-08 2002-02-28 Zmodyfikowany czynnik stymulujący tworzenie kolonii granulocytów i makrofagów (GM-CSF) o obniżonej immunogeniczności

Country Status (15)

Country Link
US (1) US7208147B2 (pl)
EP (1) EP1366074B1 (pl)
JP (1) JP2004535777A (pl)
KR (1) KR20030082962A (pl)
CN (1) CN1494551A (pl)
AT (1) ATE339446T1 (pl)
BR (1) BR0207945A (pl)
CA (1) CA2439926A1 (pl)
DE (1) DE60214682T2 (pl)
HU (1) HUP0303429A3 (pl)
MX (1) MXPA03008032A (pl)
PL (1) PL362986A1 (pl)
RU (1) RU2003129058A (pl)
WO (1) WO2002070548A2 (pl)
ZA (1) ZA200307829B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
AU2013201228B2 (en) * 2006-02-08 2016-01-21 Eisai, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
KR101395515B1 (ko) 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US9493515B2 (en) 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ, インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージg3pアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Gm-csf變體及使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity

Also Published As

Publication number Publication date
WO2002070548A2 (en) 2002-09-12
ATE339446T1 (de) 2006-10-15
WO2002070548A3 (en) 2003-05-01
EP1366074A2 (en) 2003-12-03
CA2439926A1 (en) 2002-09-12
ZA200307829B (en) 2004-07-21
MXPA03008032A (es) 2003-12-04
HUP0303429A3 (en) 2005-12-28
JP2004535777A (ja) 2004-12-02
HUP0303429A2 (hu) 2004-01-28
US7208147B2 (en) 2007-04-24
DE60214682T2 (de) 2007-09-13
DE60214682D1 (de) 2006-10-26
RU2003129058A (ru) 2005-04-20
BR0207945A (pt) 2004-07-27
KR20030082962A (ko) 2003-10-23
EP1366074B1 (en) 2006-09-13
US20040092717A1 (en) 2004-05-13
CN1494551A (zh) 2004-05-05

Similar Documents

Publication Publication Date Title
WO2002074783A3 (en) Modified interferon beta with reduced immunogenicity
WO2002062832A3 (en) Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity
WO2002085941A3 (en) Modified interferon alpha with reduced immunogenicity
WO2002062843A3 (en) Modified erythropoietin (epo) with reduced immunogenicity
MXPA03008032A (es) Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
WO2002062833A3 (en) Modified leptin with reduced immunogenicity
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
AU2210899A (en) Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
HUP0401534A2 (hu) Módosított humán IX. faktor
WO2006010143A3 (en) Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
AU2002229510A1 (en) Combined use of factor vii polypeptides and factor viii polypeptides
WO2003040398A3 (en) Proteins stabilized with polysaccharide gums
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
WO2002070698A3 (en) Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
WO2002077034A3 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
WO2020226854A3 (en) Tolerogenic artificial antigen-presenting cells
PL373795A1 (pl) Koniugaty peptydu tymozyny alfa 1 i polimeru
WO2002068469A3 (en) Modified thrombopoietin with reduced immunogenicity
ATE515258T1 (de) Mukosales verabreichungssytem
WO2003006047A3 (en) Methods for reducing immunogenicity of polypeptides
WO2004035602A3 (en) Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines
DK1173476T3 (da) Funktionelle sojabönneproteiner
WO2002074808A3 (en) Modified insulin with reduced immunogenicity

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)